- Home
- TVTX vs PEB Comparison
TVTX vs PEB Comparison
Compare TVTX & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- PEB
- Stock Information
- Founded
- TVTX 2008
- PEB 2009
- Country
- TVTX United States
- PEB United States
- Employees
- TVTX N/A
- PEB N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- PEB Real Estate Investment Trusts
- Sector
- TVTX Health Care
- PEB Real Estate
- Exchange
- TVTX Nasdaq
- PEB Nasdaq
- Market Cap
- TVTX 1.6B
- PEB 1.5B
- IPO Year
- TVTX N/A
- PEB 2009
- Fundamental
- Price
- TVTX $17.49
- PEB $14.22
- Analyst Decision
- TVTX Buy
- PEB Buy
- Analyst Count
- TVTX 13
- PEB 6
- Target Price
- TVTX $23.46
- PEB $14.92
- AVG Volume (30 Days)
- TVTX 1.1M
- PEB 1.7M
- Earning Date
- TVTX 02-13-2025
- PEB 11-07-2024
- Dividend Yield
- TVTX N/A
- PEB 0.28%
- EPS Growth
- TVTX N/A
- PEB N/A
- EPS
- TVTX N/A
- PEB N/A
- Revenue
- TVTX $203,447,000.00
- PEB $1,449,797,000.00
- Revenue This Year
- TVTX $62.17
- PEB N/A
- Revenue Next Year
- TVTX $56.38
- PEB $3.64
- P/E Ratio
- TVTX N/A
- PEB N/A
- Revenue Growth
- TVTX 57.08
- PEB 3.15
- 52 Week Low
- TVTX $5.12
- PEB $11.65
- 52 Week High
- TVTX $20.33
- PEB $16.65
- Technical
- Relative Strength Index (RSI)
- TVTX 39.02
- PEB 61.51
- Support Level
- TVTX $17.27
- PEB $14.30
- Resistance Level
- TVTX $19.20
- PEB $14.73
- Average True Range (ATR)
- TVTX 0.72
- PEB 0.33
- MACD
- TVTX -0.29
- PEB -0.03
- Stochastic Oscillator
- TVTX 3.80
- PEB 54.29
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,924 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.